NEUROCRINE BIOSCIENCES INC Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
NEUROCRINE BIOSCIENCES INC (NBIX) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 1.07 million shares for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-07.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2020-02-07
- NEUROCRINE BIOSCIENCES INC incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2018-09-30 was 2.25M shares.
- NEUROCRINE BIOSCIENCES INC incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2017-09-30 was 0.00 shares.
- NEUROCRINE BIOSCIENCES INC incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2019 was 1.07M shares, a 20.47% decline from fiscal 2018.
- NEUROCRINE BIOSCIENCES INC incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2018 was 1.35M shares.
- NEUROCRINE BIOSCIENCES INC incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2017 was 0.00 shares.
- NEUROCRINE BIOSCIENCES INC incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2016 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|
| 2019-12-31 | 1.07M shares 10-K · filed 2020-02-07 | ||
| 2018-12-31 | 1.35M shares 10-K · filed 2020-02-07 | ||
| 2018-09-30 | 2.25M shares 10-Q · filed 2018-11-05 | 1.33M shares 10-Q · filed 2018-11-05 | |
| 2017-12-31 | 0.00 shares 10-K · filed 2020-02-07 | ||
| 2017-09-30 | 0.00 shares 10-Q · filed 2018-11-05 | 0.00 shares 10-Q · filed 2018-11-05 | |
| 2016-12-31 | 0.00 shares 10-K · filed 2019-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |